Robert F. Siegmund, PhD MBA

We cannot solve problems of today and tomorrow with solutions from yesterday. Especially not in health and care! I am looking forward to joining this year’s Geneva Digital Health Day as a keynote speaker on May 30. Introducing the Novartis Foundation’s population health initiative AI4HealthyCities, I’d like to inspire timely conversations about the much-needed, deep integration of AI in fundamental health decision making processes. Only by leveraging the power of advanced analytics and AI, we will be able to decipher what drives a population’s health outcomes at scale – and act on it accordingly. Will I see you there? More information: https://lnkd.in/ejDyfe9X #PopulationHealth #HealthData #HealthEquity

114

16 Kommentare

Interesting perspective on macro-level online pharma trends. The integration of larger digital and social strategies with the sub-strategies of individual therapy area franchises is a critical consideration (and is not done to the extent it needs to be done). #Pharma #DigitalStrategy #HealthcareTrends

9

I came across this interesting article about how to improve your prompts in ChatGPT. I hope you find it useful. https://lnkd.in/ehiAnchW

4

Please join to listen to the webinar, Katarzyna Moscicka, PSI’s Head of Feasibility, discusses a recap of the European Society For Medical Oncology (ESMO) 2024 conference and some of the most exciting treatments and industry trends from this year’s presentations. Some of the #drugdevelopment topics highlighted include: Tumor Agnostic Advances in #PrecisionMedicine Novel Drug Types including #ADC and #Radioligands Artificial Intelligence (#AI) in Clinical Trial Applications About PSI’s Oncology Experience: At PSI CRO AG, over 50% of our studies are in oncology. We focus on pivotal trials in select indications to ensure our teams have both the resources and flexibility to remain leaders in delivering these challenging studies. It’s one reason that 93% of PSI oncology studies meet or beat projected #enrollment timelines. Learn more about our #oncology expertise at https://lnkd.in/gc_cv-aV #PSICRO #ESMO2024 #clinicaltrials #clinicalreseach #oncologyclinicaltrials https://lnkd.in/d4nKhF_e

4

Looking forward to attending ESMO, and discovering how Metronomia Clinical Research may further advance your cancer research. #oncology #ESMO #clinicaltrials #datascience

15

How can sites effectively leverage new diversity-focused rules and regulations to enhance trial efficiency and patient care? Hear from industry experts on how sites are adapting to these changes and how sponsors are responding to evolving models of trial execution ⇢https://lnkd.in/ecScW-zv

7

1 Kommentar

I am excited about our upcoming educational webinar focused on RWE... we already have over 100 registrations 🙂!! As you may know, national HTA bodies require comparative evidence of the effectiveness and safety of your asset against the Standard of Care in different regions. This will be even more so after implementation of the new European Joint Clinical Assessment! In addition, payors generally ignore any evidence that does not come from comparative studies. 🤔 So, what if RCT evidence isn’t available...? 🔍 Comparative Real-World Evidence (RWE) is one option to close evidence gaps. Register for our webinar with RWE expert Prof. Dr. Thomas Wilke on 17 October 2024* and learn:  ✔️ What is better and what is more accepted: comparative RWE versus indirect comparisons based on trials ✔️ Synthetic control groups and post-approval comparative RWE studies: How do they work? ✔️ Existing guidance and guidelines for comparative RWE studies 🙋 Want to register for this free educational webinar? 💬 Like and reply with YES in the comments and I’ll send you the registration link! *If you cannot attend the webinar, please note that a recorded playback will be sent to all registrants after the webinar. Please note that this webinar is only open to managers working in pharma/biotech/medtech companies. -------- ☝️ I am Inge 🔥 My mission: Helping Pharma managers acquire business-critical competencies to make better decisions Liked this post? Want to see more? 🔔 Ring the bell on my Profile to get notified 🔝 Connect with me #webinar #pharma #RWE #ComparativeRWE GIPAM

24

39 Kommentare

Here comes #SORA. #OpenAI text-to-picture is already the new normal .. here comes TEXT-TO-VIDEO. Have a look at what is possible and visit the website to look at the simple prompts for each sequence: https://lnkd.in/dQyBW9gH While watching (and there is no sound) keep in mind this is all not real and just based on a few simple prompts. The machine does the rest .. look and feel, physics, reflections, shapes and looks. What’s next?

4

Join us on June 12th in Basel to learn about the new EUHTA regulations

12

Going to EHA 2024? Connect with us to learn more about our tailored reports from the leading source of European oncology data. https://ow.ly/aLsR30sE7SS #EHA2024 #OncologyData #RealWorldResearch

23

The EU Health Technology Assessment Regulation (EU HTAR) is indeed a significant opportunity to streamline the assessment of new technologies and medicines across Europe. However, as highlighted by this article, it's crucial to address the challenges in the current scoping model to ensure the regulation meets its goals. The potential for duplication and unnecessary complexity in the PICOs process could delay patient access to essential medicines. It's vital that the HTA Coordination Group and Member States prioritize evidence-based approaches and involve the relevant stakeholders to truly benefit patients, accelerate access and support innovation in the EU.

42

EU Health Technology Assessment Regulation (EU HTAR) is a unique opportunity to make a step change in the efficiency and speed of assessing new technologies and medicines across Europe. By reducing duplication of HTA processes, it has the potential to make patient access to new medicines and technologies faster and more equitable. This will lead to improved patient outcomes, which is also an important goal for us at AstraZeneca. I’d like to highlight the work of my colleague James Ryan who has collaborated with EFPIA - European Federation of Pharmaceutical Industries and Associations and IQVIA to develop this research manuscript in ISPOR—The Professional Society for Health Economics and Outcomes Research Value in Health journal: https://bit.ly/3z4xZ4Y This in press article illustrates some challenges of the proposed scoping model from EUnetHTA 21 for the EU HTAR, which risk jeopardising the Regulation’s aims in several ways: * The approach to defining and consolidating the populations, intervention, comparators and outcomes (PICOs), which is a critical component of the Joint Clinical Assessment (JCA), is currently unclear and demonstrates a potentially additive, instead of a harmonised, approach. * The impact of the proposed scoping process alongside the recent inclusion of many additional safety outcomes in the JCA method guidance will have assessors requesting thousands of analyses for each JCA – many of which are currently not required in Europe and not actually used by decision-makers. * The research, consistent with other studies, shows that the current proposal will result in PICOs in the double digits, creating extra and unnecessary work for both the Health Technology Developers and assessors, thus delaying review and ultimately access to patients. All stakeholders are aligned on the ambition of creating a transparent and evidence-based HTA across the EU, which has optimal impact for patients while being workable and efficient for assessors and health technology developers. This will also increase Europe's competitiveness as a life science region, driving and accelerating future innovation. But to successfully achieve the HTAR aims, we need the HTA Coordination Group and Member States, through their HTA bodies, to use evidence-based principles to inform national policy questions, as recommended by the World Health Organization. Reliable evidence and those representing the largest patient populations should be prioritised in evaluation of PICOs, with complementary analyses used where possible across Member States. I hope this research and other reviews will build consensus around the need to address these challenges, which will enable HTAR to achieve its goals. Megan Yuan Sandro Cesaro Shane Elder Christine Ney, R.Ph., Pharm.D. Daniel Widrig

85

💡 Eco-pharmacovigilance is the science and activities concerning the detection, assessment, understanding, and prevention of adverse effects related to the presence of pharmaceuticals in the environment, which may affect humans and other animal species. Klaudija Marijanovic-Barac, from our #Pharmacovigilance and Patient Safety (PV) team, explains the importance of eco-pharmacovigilance for promoting better health for all >> https://lnkd.in/expTiNba

2

Please read this perspective on pragmatic clinical trials, as we listen to the many studies reported out at ESMO. #oncologyclincialtrials

64

2 Kommentare

⚡ Big news from STADA Group and Calliditas Therapeutics today! The European Commission granted full marketing authorization to #Kinpeygo for the treatment of primary IgAN patients. The approval results in a broader label for patients with primary IgAN, moving from a UPCR limit of >1.5g/g to a UPCR of ≥ 0.8g/g. 💡 Data from Spherix's most recent EU5 IgAN patient chart audit showed a year-over-year increase in Kinpeygo use, while nephrologists also positioned the drug as a prominent next likely treatment for many of their IgAN patients who were not currently on therapy. It will be interesting to see how the patient pool shifts following this update and with #Filspari's market entrance later this year. Read more here: https://lnkd.in/eVGeMak9 #IgAN #nephrology #marketresearch

8

Interesting article! According to article below the digital maturity hasn't progressed over the last year, despite many new offerings and clever software's. Reasons being: - Challenges for op's teams - Transitions taking longer time than anticipated - Financial burden Are you also finding it difficult to add new tech/processes currently? Why? #clinicaltrials #digitalization https://lnkd.in/dPhKXJpU

12

Think the Unthinkable… Federico Faggin’s claim that consciousness is the foundation of the universe turns conventional science on its head. Rather than seeing consciousness as a byproduct of matter, he flips the relationship - an idea as bold as it is reminiscent of great metaphysicians. But as inspiring as this notion is, the question of proof remains. The “Hard Problem of Consciousness” still stands: how do physical processes generate subjective experience? Faggin challenges us to push the boundaries of science. His approach, treating consciousness as the primary substance, sparks a thrilling philosophical debate, even without empirical evidence. But it’s precisely these speculative ideas that drive progress. He reminds us that the greatest discoveries often begin with the courage to think the unthinkable. If consciousness comes before matter, how should we rethink our understanding of the mind and reality? What’s your view on this?

6

6 Kommentare